Dean A. Falb

Nessuna posizione attualmente

63 anni

Health Technology

Consumer Services

Profilo

Dean A.
Falb worked as Vice President-Research & Development at Stryker Corp.
from 2005 to 2012.
He also worked as Senior Vice President-Research & Development at Praecis Pharmaceuticals, Inc. and as Chief Scientific Officer at LogicBio Therapeutics, Inc. In 2013, he became the Chief Technology Officer at Synlogic, Inc. Dr. Falb holds a doctorate degree from Harvard University and an undergraduate degree from Purdue University.

Precedenti posizioni note di Dean A. Falb

Società	Posizione	Fine
SYNLOGIC, INC.	Chief Tech/Sci/R&D Officer	01/05/2018
STRYKER CORPORATION	Chief Tech/Sci/R&D Officer	01/01/2012
LOGICBIO THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	-
Praecis Pharmaceuticals, Inc. Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.	Chief Tech/Sci/R&D Officer	-

Vedi nel dettaglio l'esperienza di Dean A. Falb

Formazione di Dean A. Falb

Harvard University	Doctorate Degree
Purdue University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Dean A. Falb

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
STRYKER CORPORATION	Health Technology
SYNLOGIC, INC.	Health Technology

Aziende private	2
Praecis Pharmaceuticals, Inc. Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.	Health Technology
LogicBio Therapeutics, Inc. LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.	Health Technology